渐冻症（ALS）之TDP

[1] Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017 Oct 5;3:17071.

[2] Gregory, J.M., Fagegaltier, D., Phatnani, H. et al. Genetics of Amyotrophic Lateral Sclerosis. Curr Genet Med Rep 8, 121–131 (2020).

[3] Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022 Oct 15;400(10360):1363-1380. 

[4] Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020 Aug 15;15(1):45.

[5] Lépine S, Castellanos-Montiel MJ, Durcan TM. TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis. Transl Neurodegener. 2022 Dec 27;11(1):56.

[6] Hayes LR, Kalab P. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics. 2022 Jul;19(4):1061-1084.

[7] Francois-Moutal L, Scott DD, Khanna M. Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. RSC Chem Biol. 2021 Jun 21;2(4):1158-1166.

[8] Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol. 2021 Mar;178(6):1298-1315.

[9] ALS News Today. (n.d.). ALS Gene Therapy SOL-257 Targeting TDP-43 Shows Promise in Mouse Model. Retrieved from https://alsnewstoday.com/news/als-gene-therapy-sol-257-targeting-tdp-43-shows-promise-mouse-model/

[10]  ALS News Today. (n.d.). Vectory Raises Millions to Advance ALS Antibody Therapy TDP-43. Retrieved from https://alsnewstoday.com/news/vectory-raises-millions-advance-als-antibody-therapy-tdp-43

[11]  ALS News Today. (n.d.). Takeda Acquires License for ALS Therapy Aimed at Toxic TDP-43. Retrieved from https://alsnewstoday.com/news/takeda-acquires-license-als-therapy-aimed-toxic-tdp-43/